Understanding genetics, genomics, and their utility in prostate cancer

Our friends at UroToday have just published a perfectly lovely lecture on this topic given by Prof. Lenny Gomella at the recent annual meeting of the Large Urology Group Practice Association (LUGPA). … READ MORE …

More reports from the EAU “Update on Prostate Cancer”

Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …

Genetics, PSA, and steps toward a better prostate cancer risk management strategy

A new analysis of a large data set compiled by Kaiser Permanente suggests that combining PSA data with genetic risk data may offer a much more effective way to assess risk for clinically significant prostate cancer. … READ MORE …

Predicting the future: what Genomic Health isn’t telling us (yet)

A media release issued  yesterday by Genomic Health, Inc., has suggested that the multi-gene Oncotype DX® Genomic Prostate Score™ is a strong predictor of risk for the development of metastasis and prostate cancer death in patients with early-stage prostate cancer. … READ MORE …

What’s happening at the annual EAU meeting in Munich?

So our friends at UroToday have started providing reports on the key presentations that are being given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. Here are links to some interesting reports … READ MORE …

Pathway Genomics’ Cancer Intercept test has a problem

Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we expected the U.S. Food and Drug Administration (FDA) would have some comments on the promotion of this test. We were correct. … READ MORE …

Genetics, genomics, targeted therapy, and “personalized” cancer care

If you are still under the illusion that, simply by identifying the precise structure of the deoxyribonucleic acid (DNA) of patients’ cancer cells, we will be able to develop and target drugs that can eliminate specific cancers (or indeed other disorders) in specific individuals, an article by Sharon Begley on the Reuters.com web site should help to disabuse you. … READ MORE …